

THIS PAGE IS INSERTED BY OIPE SCANNING

IMAGES WITHIN THIS DOCUMENT ARE BEST AVAILABLE COPY AND CONTAIN DEFECTIVE IMAGES SCANNED FROM ORIGINALS SUBMITTED BY THE APPLICANT.

DEFECTIVE IMAGES COULD INCLUDE BUT ARE NOT LIMITED TO:

BLACK BORDERS

TEXT CUT OFF AT TOP, BOTTOM OR SIDES

FADED TEXT ✓

ILLEGIBLE TEXT

SKEWED/SLANTED IMAGES

COLORED PHOTOS

BLACK OR VERY BLACK AND WHITE DARK PHOTOS

GRAY SCALE DOCUMENTS

**IMAGES ARE BEST AVAILABLE COPY.
RESCANNING DOCUMENTS *WILL NOT*
CORRECT IMAGES.**

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : KUKOLJ, G. et al) Art Unit: To be assigned
U.S. Appln. No. : To be assigned) Examiner: To be assigned
Confirmation No. : To be assigned
U.S. Filing Date : October 16, 2003
Title of Invention : Self-replicating RNA Molecule from Hepatitis C Virus
Attny. Docket No.: 13/083-2-C1

Commissioner for Patents
P. O. Box 1450
Alexandria, VA 22313-1450

October 16, 2003

TRANSMITTAL LETTER FOR INFORMATION DISCLOSURE STATEMENT

Sir:

Transmitted herewith concerning the subject application is an Information Disclosure Statement (Form 1449A/B) under 37 C.F.R. §§1.56 and 1.97, as more specifically described herein below. A copy of each of the non-patent documents can be found in the parent case, U.S. Patent Application Serial No. 10/029,907, filed December 21, 2001. A copy of each of the two U.S. Patent application publications is not submitted pursuant to waiver of 37 CFR § 1.98 (a)(2).

☒ 1.97(b). This Statement is being filed: i) within three (3) months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. §1.53 (d); ii) within three (3) months of the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in an international application; iii) before the mailing of a first Office action on the merits; or iv) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. §1.114.

☐ 1.97(c). This Statement is being filed after the time period specified in 37 C.F.R. §1.97(b), but before the mailing date of: i) a final action under 37 C.F.R. §1.113, ii) a notice of allowance under 37 C.F.R. §1.311, or iii) an action that otherwise closes prosecution in the application. This Statement is being accompanied by:

☐ A statement as specified in 37 C.F.R. §1.97(e) [see below]; or

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.97(d). This Statement is being filed after the period specified in 37 C.F.R. §1.97(c) but on or before payment of the issue fee. This Statement is accompanied by a statement as specified in 37 C.F.R. §1.97(e) [see below] and the fee set forth in 37 C.F.R. §1.17(p).

☐ 1.97(e).

☐ Each item of information contained in the instant information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three (3) months prior to the filing of the instant information disclosure statement; or

☐ No item of information contained in the instant information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this certification after making reasonable inquiry, no item of information contained in the instant information disclosure statement was known to any individual designated in 37 C.F.R. §1.56(c) more than three (3) months prior to the filing of the instant information disclosure statement.

☐ The fee set forth in 37 C.F.R. §1.17(p).

☐ The Commissioner is hereby authorized to charge payment of the \$180.00 fee set forth in 37 C.F.R. §1.17(p) to Deposit Account No. 02-2955.

☐ 1.704(d). Each item of information contained in the accompanying information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, which communication was not received by any individual designated in section 1.56(c) more than thirty (30) days prior to the filing of the accompanying information disclosure statement.

☒ The Commissioner is hereby authorized to charge payment of any additional filing fees required under 37 C.F.R. §1.16 and any patent application processing fees under 37 C.F.R. §1.17, or credit any overpayment of same, to Deposit Account No. 02-2955.

Triplicate copies of this form are enclosed.

Respectfully submitted,



Susan K. Pocchiari
Attorney for Applicant(s)
Reg. No. 45,016


Patent Department
Boehringer Ingelheim Corp.
900 Ridgebury Road, P.O. Box 368
Ridgefield, CT 06877
Tel: (203) 798-4868
Date: October 16, 2003

Certificate of Mailing

I hereby certify that this correspondence is being deposited with the U.S. Postal Service with sufficient postage as Express mail in an envelope addressed to:

Mail Stop Patent Application
Commissioner For Patents
P. O. Box 1450
Alexandria, VA 22313-1450

on October 16, 2003.



Susan K. Pocchiari, Reg. No. 45,016

13/083-2-C1

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

2

of

5

Complete if Known

Application Number

To be assigned

Filing Date

October 16, 2003

First Named Inventor

G. KUKOLJ, et al

Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

13/083-2-C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		FOURNIER, SUREAU et al.; In vitro infection of adult normal human hepatocytes in primary culture by hepatitis C virus; J. Virol.; 1998, V. 79; 2367-2374	
		GRAKOU, WYCHOWSKI et al.; Expression and Identification of Hepatitis C Virus Polypeptide Cleavage Products; J. Virol.; 1993, V. 67, No. 3; 1385-1395	
		HIJIKATA, MIZUSHIMA et al.; Two Distinct Proteinase Activities Required for the Processing of a Putative Nonstructural Precursor Protein of Hepatitis C Virus; J. Virol.; 1993, V. 67, No. 8; 4665-4675	
		BARTENSCHLAGER, AHLBORN-LAAKE et al.; Nonstructural Protein 3 of the Hepatitis C Virus Encodes a Serine-Type Proteinase Required for Cleavage at the NS3/4 and NS4/5 Junctions; J. Virol.; 1993, V. 67, No. 7; 3835-3844	
		REED, XU et al.; Phosphorylation of the Hepatitis C Virus NS5A Protein In Vitro and In Vivo: Properties of the NS5A-Associated Kinase; J. Virol.; 1997, V. 71, No. 10; 7187-7197	
		KHROMYKH, WESTAWAY; Subgenomic Replicons of the Flavivirus Kunjin: Construction and Applications; J. Virol.; 1997, V. 71, No. 2; 1497-1505	
		BEHRENS, GRASSMANN et al.; Characterization of an Autonomous Subgenomic Pestivirus RNA Replicon; J. Virol.; 1998, V. 72, No. 3; 2364-2372	
		MIZUTANI, KATO et al.; Characterization of Hepatitis C Virus Replication in Cloned Cells Obtained from a Human T-Cell Leukemia Virus Type 1-Infected Cell Line, MT-2; J. Virol.; 1996, V. 70, No. 10; 7219-7223	
		MOSER, TRATSCHIN et al.; A Recombinant Classical Swine Fever Virus Stably Expresses a Marker Gene; J. Virol.; 1998, V. 72, No. 6; 5318-5322	
		KEDA, SUGIYAMA et al.; Human hepatocyte clonal cell lines that support persistent replication of hepatitis C virus; Virus Research; 1998, V. 56; 157-167	

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

3

of

5

Complete if Known

Application Number	To be assigned
Filing Date	October 16, 2003
First Named Inventor	G. KUKOLJ, et al
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	13/083-2-C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		DASH, HALIM et al.; Transfection of HepG2 Cells with Infectious Hepatitis C Virus Genome; Amer. J. Pathology; 1997, V. 151; 363-373	
		KWONG, KIM et al.; Hepatitis C Virus NS3/4A protease; Antiviral Research 1998, V. 40; 1-18	
		LANFORD, SUREAU et al; Demonstration of in Vitro Infection of Chimpanzee Hepatocytes with hepatitis C Virus Using Strand-Specific RT/PCR; Virology; 1994, V. 202; 606-614	
		LESBURG, CABLE et al; Crystal structure of the RNA-dependent RNA polymerase from hepatitis C virus reveals a fully encircled active site; Nat. Struc. Biolo; 1999 V.6 No. 10; 937-943	
		LOHMANN, KORNER et al; Replication of Subgenomic Hepatitis C Virus RNAs in a Hepatoma Cell Line; Science; 1999, V.285; 110-113	
		LOHMANN, KORNER et al; Mutations in Hepatitis C virus RNAs Confering Cell Culture Adaptation; J. Virology; 2001, V. 75, No. 3, 1437-1449	
		LOVE, PARGE et al; The Crystal Structure of Hepatitis C Virus NS3 Proteinase Reveals a Trypsin-like Fold and a Structural Zinc Binding Site; Cell; 1996, V. 87, 331-342	
		SHIMIZU, Purcell et al; Correlation between the infectivity of hepatitis C virus in vivo and its infectivity in vitro; Proc. Natl. Acad. Sci. USA; 1993, V. 90; 6037-6041	
		YANAGI, ST. CLAIRE et al; In vivo analysis of the 3' untranslated region of the hepatitis C virus after in vitro mutagenesis of an infectious cDNA clone; Proc. Natl. Acad. Sci. USA 1999, V. 96, 2291-2295	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

4

of

5

Complete if Known

Application Number

To be assigned

Filing Date

October 16, 2003

First Named Inventor

G. KUKOLJ, et al

Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

13/083-2-C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		BRESSANELLI, TOMEI et al.; Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus; PNAS; 1999, V. 96, No. 23; 13034-13039	
		KIM, MORGENSTERN et al.; Hepatitis C virus NS3 RNA helicase domain with a bound oligonucleotide: the crystal structure provides insights into the mode of unwinding; Structure; 1998, V. 6; 89-100	
		YAN, LI et al.; Complex of NS3 protease and NS4A peptide of BK strain hepatitis C virus; A 2.2 A resolution structure in a hexagonal crystal form; Protein Science; 1998, V. 7; 837-847	
		YAO, HESSON et al.; Structure of the hepatitis C virus RNA helicase domain; Nature Structural Biology; 1997, V. 4, No. 6; 463-467	
		ITO, MUKAIGAWA et al.; Cultivation of hepatitis C virus in primary hepatocyte culture from patients with chronic hepatitis C results in release of high titre infectious virus; J. Gen. Virol.; 1996, V. 77; 1043-1054	
		YOO, SELBY et al.; Transfection of a Differentiated Human Hepatoma Cell Line (Huh7) with In Vitro-Transcribed Hepatitis C Virus (HCV) RNA and Establishment of a Long-Term Culture Persistently Infected with HCV; J. Virol.; 1992, V. 69, No. 1; 32-38	
		AGO, ADACHI et al.; Crystal structure of the RNA-dependent RNA polymerase of hepatitis C virus; Structure; 1999, V. 7; 1417-1426	
		BLIGHT, KOLYKHALOV et al.; Efficient Initiation of HCV RNA Replication in Cell Culture; Science; 2000, V. 290; 1972-1974	

Examiner
SignatureDate
Considered

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

5

of

5

Complete if Known

Application Number

To be assigned

Filing Date

October 16, 2003

First Named Inventor

G. KUKOLJ, et al

Art Unit

To be assigned

Examiner Name

To be assigned

Attorney Docket Number

13/083-2-C1

NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
		CHO, HA et al.; Crystal Structure of RNA Helicase from Genotype 1b Hepatitis C Virus; J. Biol. Chemistry; 1998, V. 273, No. 24; 15054-15052	
		GALE JR., KORTH et al.; Evidence that Hepatitis C Virus Resistance to Interferon is Mediated through Repression of the PKR Protein Kinase by the Nonstructural 5A Protein; Virology; 1997, V. 230: 217-227	
		GRAKOU, MCCOURT et al.; A second hepatitis C virus-encoded proteinase; Proc. Natl. Acad. Sci. USA; 1993, V. 90; 10583-10587	
		GOU, JU-TAO et al.; Effect of Alpha Interferon on the Hepatitis C virus Replicon; J. Virol.; 2001, 75(18):8516-8523	
		HIJIKATA, MAKOTO et al.; Gene mapping of the putative structural region of the hepatitis C virus genome by in vitro processing analysis; Proc. Natl. Acad. Sci.; 1991, 88:5547-5551	
		KIM, DONG WOOK et al.; C-Terminal Domain of the Hepatitis C Virus NS3 Protein Contains an RNA Helicase Activity; 1995, 215(1):160-166	
		KIM, J.-E. et al.; Subcellular localization of hepatitis C viral proteins in mammalian cells; Arch Virol.; 1999, 144:329-343	
		KIM, J.L. et al; Crystal Structure of the Hepatitis C Virus NS3 Protease Domain Complexed with a Synthetic NS4A Cofactor Peptide; Cell; 1996, 87:343-355	
		KRIEGER, NICOLE, et al; Enhancement of Hepatitis C Virus RNA Replication by Cell Culture-Adaptive Mutations; J. of Virol.; 2001, 75(10):4614-4624	
		International Search Report issued March 3, 2003 for PCT/CAD1/01843 the counterpart of Parent U.S. Application 10/029,907.	

Examiner Signature	Date Considered
-----------------------	--------------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.